GB201223265D0 - Novel benzimidazole derivatives as kinase inhibitors - Google Patents

Novel benzimidazole derivatives as kinase inhibitors

Info

Publication number
GB201223265D0
GB201223265D0 GBGB1223265.8A GB201223265A GB201223265D0 GB 201223265 D0 GB201223265 D0 GB 201223265D0 GB 201223265 A GB201223265 A GB 201223265A GB 201223265 D0 GB201223265 D0 GB 201223265D0
Authority
GB
United Kingdom
Prior art keywords
kinase inhibitors
benzimidazole derivatives
novel benzimidazole
novel
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1223265.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selvita Sp zoo
Original Assignee
Selvita Sp zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita Sp zoo filed Critical Selvita Sp zoo
Priority to GBGB1223265.8A priority Critical patent/GB201223265D0/en
Publication of GB201223265D0 publication Critical patent/GB201223265D0/en
Priority to US14/654,779 priority patent/US9388192B2/en
Priority to CA2896156A priority patent/CA2896156C/en
Priority to HUE13811246A priority patent/HUE039376T2/hu
Priority to AU2013366513A priority patent/AU2013366513B2/en
Priority to LTEP13811246.1T priority patent/LT2935244T/lt
Priority to ES13811246.1T priority patent/ES2688395T3/es
Priority to JP2015548646A priority patent/JP6169185B2/ja
Priority to PL13811246T priority patent/PL2935244T3/pl
Priority to PCT/EP2013/077754 priority patent/WO2014096388A2/en
Priority to EP13811246.1A priority patent/EP2935244B1/en
Priority to CN201380067040.1A priority patent/CN104936951B/zh
Priority to PT13811246T priority patent/PT2935244T/pt
Priority to BR112015014701A priority patent/BR112015014701B8/pt
Priority to SM20180473T priority patent/SMT201800473T1/it
Priority to MX2015007057A priority patent/MX369589B/es
Priority to KR1020157019215A priority patent/KR101779272B1/ko
Priority to SI201331149T priority patent/SI2935244T1/sl
Priority to HRP20181429TT priority patent/HRP20181429T8/hr
Priority to DK13811246.1T priority patent/DK2935244T3/en
Priority to RS20181052A priority patent/RS57658B1/sr
Priority to IL239193A priority patent/IL239193A0/en
Priority to US15/179,601 priority patent/US10174013B2/en
Priority to CY181100977T priority patent/CY1120692T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB1223265.8A 2012-12-21 2012-12-21 Novel benzimidazole derivatives as kinase inhibitors Ceased GB201223265D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB1223265.8A GB201223265D0 (en) 2012-12-21 2012-12-21 Novel benzimidazole derivatives as kinase inhibitors
RS20181052A RS57658B1 (sr) 2012-12-21 2013-12-20 Novi derivati benzimidazola kao inhibitori kinaza
EP13811246.1A EP2935244B1 (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors
PT13811246T PT2935244T (pt) 2012-12-21 2013-12-20 Novos derivados de benzimidazole como inibidores de quinases
HUE13811246A HUE039376T2 (hu) 2012-12-21 2013-12-20 Új kináz-inhibitor benzimidazol-származékok
AU2013366513A AU2013366513B2 (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors
LTEP13811246.1T LT2935244T (lt) 2012-12-21 2013-12-20 Nauji benzimidazolo dariniai, kaip kinazės inhibitoriai
ES13811246.1T ES2688395T3 (es) 2012-12-21 2013-12-20 Derivados de bencimidazol novedosos como inhibidores de cinasa
JP2015548646A JP6169185B2 (ja) 2012-12-21 2013-12-20 キナーゼ阻害剤としての新規ベンゾイミダゾール誘導体
PL13811246T PL2935244T3 (pl) 2012-12-21 2013-12-20 Nowe pochodne benzimidazolu jako inhibitory kinazy
PCT/EP2013/077754 WO2014096388A2 (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors
US14/654,779 US9388192B2 (en) 2012-12-21 2013-12-20 Benzimidazole derivatives as Kinase Inhibitors
CN201380067040.1A CN104936951B (zh) 2012-12-21 2013-12-20 作为激酶抑制剂的苯并咪唑衍生物
CA2896156A CA2896156C (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors
BR112015014701A BR112015014701B8 (pt) 2012-12-21 2013-12-20 Derivados de benzimidazol e seus usos
SM20180473T SMT201800473T1 (it) 2012-12-21 2013-12-20 Nuovi derivati di benzimidazolo come inibitori di chinasi
MX2015007057A MX369589B (es) 2012-12-21 2013-12-20 Derivados novedosos de bencimidazol como inhibidores de cinasas.
KR1020157019215A KR101779272B1 (ko) 2012-12-21 2013-12-20 키나제 억제제로서의 신규 벤즈이미다졸 유도체
SI201331149T SI2935244T1 (sl) 2012-12-21 2013-12-20 Novi benzimidazolni derivati kot inhibitorji kinaze
HRP20181429TT HRP20181429T8 (hr) 2012-12-21 2013-12-20 Novi derivati benzimidazola kao inhibitori kinaze
DK13811246.1T DK2935244T3 (en) 2012-12-21 2013-12-20 UNTIL UNKNOWN BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS
IL239193A IL239193A0 (en) 2012-12-21 2015-06-03 New Benzimidazole Derivatives as Kinase Inhibitors
US15/179,601 US10174013B2 (en) 2012-12-21 2016-06-10 Benzimidazole derivatives as kinase inhibitors
CY181100977T CY1120692T1 (el) 2012-12-21 2018-09-20 Καινοφανη παραγωγα βενζιμιδαζολης ως αναστολεις κινασων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1223265.8A GB201223265D0 (en) 2012-12-21 2012-12-21 Novel benzimidazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
GB201223265D0 true GB201223265D0 (en) 2013-02-06

Family

ID=47682482

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1223265.8A Ceased GB201223265D0 (en) 2012-12-21 2012-12-21 Novel benzimidazole derivatives as kinase inhibitors

Country Status (23)

Country Link
US (2) US9388192B2 (enExample)
EP (1) EP2935244B1 (enExample)
JP (1) JP6169185B2 (enExample)
KR (1) KR101779272B1 (enExample)
CN (1) CN104936951B (enExample)
AU (1) AU2013366513B2 (enExample)
BR (1) BR112015014701B8 (enExample)
CA (1) CA2896156C (enExample)
CY (1) CY1120692T1 (enExample)
DK (1) DK2935244T3 (enExample)
ES (1) ES2688395T3 (enExample)
GB (1) GB201223265D0 (enExample)
HR (1) HRP20181429T8 (enExample)
HU (1) HUE039376T2 (enExample)
IL (1) IL239193A0 (enExample)
LT (1) LT2935244T (enExample)
MX (1) MX369589B (enExample)
PL (1) PL2935244T3 (enExample)
PT (1) PT2935244T (enExample)
RS (1) RS57658B1 (enExample)
SI (1) SI2935244T1 (enExample)
SM (1) SMT201800473T1 (enExample)
WO (1) WO2014096388A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
WO2015108861A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2015328174B2 (en) 2014-10-06 2020-05-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
AU2017240685B2 (en) 2016-03-31 2021-08-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JOP20190042B1 (ar) 2016-09-30 2021-08-17 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
JOP20190125B1 (ar) 2016-12-09 2022-03-14 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
US9855255B1 (en) 2017-05-26 2018-01-02 King Saud University Substituted naphthyridinyl hydrazines as anti-liver cancer agents
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR102697255B1 (ko) 2017-10-19 2024-08-23 데이진 화-마 가부시키가이샤 벤즈이미다졸 유도체 및 이의 용도
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2021096314A1 (ko) * 2019-11-15 2021-05-20 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
CN113491691B (zh) * 2020-04-02 2023-04-14 深圳贝瑞生物医药科技有限公司 一种用于制备抗肿瘤药物或14-3-3η蛋白抑制剂的化合物
KR102854745B1 (ko) 2020-04-23 2025-09-04 진크래프트 주식회사 R-point 조절 단백질 복합체를 유효성분으로 포함하는 폐암 치료용 약학적 조성물, 상기 복합체의 형성 여부를 이용한 폐암 치료제 스크리닝 방법 및 폐암 진단 방법
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
CN119816307A (zh) 2022-07-29 2025-04-11 雷沃医疗有限公司 包含flt3抑制剂的癌症组合疗法
CA3259243A1 (en) 2022-07-29 2024-02-01 Berlin-Chemie Ag CANCER POLYTHERAPY INCLUDING A BCL-2 INHIBITOR
AR132055A1 (es) * 2023-03-06 2025-05-21 Insilico Medicine Ip Ltd Inhibidores duales de cdk8/19 y métodos de uso de los mismos
CN120004808B (zh) * 2023-11-15 2025-11-25 宜昌人福药业有限责任公司 一种2-溴-5,6-二氯-1h-苯并咪唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1469504A (fr) * 1964-10-22 1967-02-17 Fisons Pest Control Ltd Composés insecticides
GB1122988A (en) 1964-10-22 1968-08-07 Fisons Pest Control Ltd Benzimidazole derivatives
DE3227893A1 (de) * 1982-07-26 1984-01-26 Macherey-Nagel & Co Chemikalienhandel, 5160 Düren Verwendung von benzimidazolderivaten zum nachweis von blut und anderen peroxidatisch wirksamen substanzen in koerperfluessigkeiten und ausscheidungsprodukten, insbesondere als diagnostikum in form eines testpapiers
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
EP1017682A4 (en) * 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
ATE259789T1 (de) * 1998-11-27 2004-03-15 Abbott Gmbh & Co Kg Substituierte benzimidazole und ihre verwendung als parp inhibitoren
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US20090131470A1 (en) 2005-06-11 2009-05-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
RU2012120784A (ru) * 2009-11-12 2013-12-20 Селвита С.А. Соединение, способ его получения, фармацевтическая композиция, применение соединения, способ модулирования или регулирования сериновых/треониновых киназ и средство, модулирующее сериновые/треониновые киназы
BR112015004858A2 (pt) * 2012-09-05 2017-07-04 Bayer Cropscience Ag uso de 2-amidobenzimidazóis, 2-amidobenzoxazóis e 2-amidobenzotiazóis substituídos ou sais dos mesmos como substâncias ativas contra estresse abiótico em plantas
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors

Also Published As

Publication number Publication date
HUE039376T2 (hu) 2018-12-28
BR112015014701A2 (pt) 2017-07-11
WO2014096388A2 (en) 2014-06-26
JP2016503779A (ja) 2016-02-08
IL239193A0 (en) 2015-07-30
DK2935244T3 (en) 2018-09-10
KR101779272B1 (ko) 2017-09-18
US20150336967A1 (en) 2015-11-26
PT2935244T (pt) 2018-10-22
CN104936951B (zh) 2018-02-06
MX2015007057A (es) 2016-01-20
CA2896156A1 (en) 2014-06-26
BR112015014701B8 (pt) 2022-12-13
RS57658B1 (sr) 2018-11-30
JP6169185B2 (ja) 2017-07-26
US20170152249A1 (en) 2017-06-01
MX369589B (es) 2019-11-13
CY1120692T1 (el) 2019-12-11
PL2935244T3 (pl) 2019-02-28
HRP20181429T8 (hr) 2018-12-28
WO2014096388A3 (en) 2014-08-21
SI2935244T1 (sl) 2019-01-31
CA2896156C (en) 2018-05-22
US10174013B2 (en) 2019-01-08
AU2013366513A1 (en) 2015-06-11
KR20150095908A (ko) 2015-08-21
CN104936951A (zh) 2015-09-23
US9388192B2 (en) 2016-07-12
EP2935244A2 (en) 2015-10-28
EP2935244B1 (en) 2018-06-27
BR112015014701B1 (pt) 2022-11-01
AU2013366513B2 (en) 2016-09-01
ES2688395T3 (es) 2018-11-02
LT2935244T (lt) 2018-10-25
SMT201800473T1 (it) 2018-11-09
HRP20181429T1 (hr) 2018-11-30

Similar Documents

Publication Publication Date Title
IL239193A0 (en) New Benzimidazole Derivatives as Kinase Inhibitors
IL261282A (en) Furinone compounds as kinase inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
LT2917217T (lt) Pakeistieji tricikliniai benzimidazolai kaip kinazės inhibitoriai
ZA201406078B (en) Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors
LT3181567T (lt) Pirazolpirimidino junginiai kaip kinazės slopikliai
SMT201700052T1 (it) 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
ZA201301951B (en) Benzimidazole derivatives as p13 kinase inhibitors
AP2013007252A0 (en) Heterocyclic compounds as kinase inhibitors
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201502838B (en) Quinazolinone derivatives as parp inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
LT2912041T (lt) Tetrahidropiroltiazino dariniai kaip bace slopikliai
EP2838531A4 (en) INDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
EP2895166A4 (en) AMINOISOQUINOLINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
EP2847186A4 (en) SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER
IL235935A0 (en) Transmutable kinase inhibitor picolinamides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)